Loading...
Celebrating a 20-year milestone, the 2023 ASCO Gastrointestinal Cancers Symposium, held January 19 to 21 in San Francisco, was a key venue for important and awaited trial results across the spectrum of gastrointestinal malignancies. NEJM Journal Watch Oncology and Hematology Associate Editor David H. Ilson, MD, PhD, reports on some of the most clinically impactful presentations. Abstracts can be viewed in the symposium's meeting library.
In the phase 3 NRG/RTOG trial 1112, researchers compared sorafenib alone versus sorafenib plus stereotactic body radiotherapy (SBRT) in advanced hepatocellular cancer (HCC; abstract 489). Patients with HCC not amenable to surgery,…